肺表面活性物质的临床应用进展  

Clinical application advancement of pulmonary surfactant

作　　者：徐国成[1] 李志奇[1] 

机构地区：[1]皖南医学院弋矶山医院儿科

出　　处：《中国临床药理学与治疗学》2010年第7期832-835,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：肺泡表面活性物质是Ⅱ型肺泡上皮细胞合成的一种磷脂-蛋白复合物,具有降低肺泡表面张力、维持肺泡稳定性、减少肺泡中液体外渗、预防肺水肿、促进气道的清除功能、抑制支气管收缩及增加肺免疫功能、减轻炎症反应、提高肺抗感染能力等多种作用。天然肺泡表面活性物质和合成肺泡表面活性物质制剂经气管注人或雾化吸人,临床治疗原发性肺泡表面活性物质缺乏性疾病及各种继发性肺泡表面活性物质缺乏相关性疾病具有一定疗效。Pulmonary surfactant is a type of a phospholipid-protein complexes synthesized by II alveolar epithelial cells. It has many functions as decreasing alveolar surface tension to maintain alveolar stability, reducing alveolar fluid extravasation in the prevention of pulmonary edema, promoting the clearance of inlet ability, inhibiting bronchoconstriction and increasing the pulmonary immune function, reducing the inflammation and improving the lung anti-infection. The natural and synthetic surfactant preparations have some therapeutic effects on the clinical treatment of primary pulmonary surfactant deficiency disease and various secondary pulmonary surfactant-related diseases through tracheal injection or inhalation.

关 键 词：肺泡表面活性物质 呼吸窘迫综合征 胎粪吸入综合征 

分 类 号：R72[医药卫生—儿科]